Lymphoproliferative Disorders: all 234 studies
Page 1 of 3. Open to participants first (46), then studies with results posted, then the rest; newest registration first within each.
- Comparison of Serratus Posterior Superior Intercostal Plane Block and Deep Serratus Anterior Plane Block After Video-Assisted Thoracoscopic SurgeryNot yet recruitingNCT07553195Not applicable
- A Comprehensive Register Of Lymphoproliferative Disorders (ReLy)RecruitingNCT07519356
- Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)RecruitingNCT07445984Not applicable
- Feasibility of a Multi-omics Platform for Hematological MalignanciesRecruitingNCT07445438Not applicable
- DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.RecruitingNCT07440290Phase 2/3
- Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)RecruitingNCT07308886Phase 2
- A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple MyelomaRecruitingNCT07075185Phase 1
- Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T/NK Lymphoproliferative Disease (EBV-T/NK LPD) and Prevention of Post Transplant Graft-versus-host DiseaseRecruitingNCT07029958Phase 4
- Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)RecruitingNCT06954805Phase 2
- Cell Population Data in CLPD and Viral DiseaseNot yet recruitingNCT06893640
- Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx TRG AssayNot yet recruitingNCT06876571
- CAR-NK Cells Production and Expansion From Patients With Lympho or Myeloproliferative Disorders and From Healthy DonorsRecruitingNCT06727383Not applicable
- An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative DisordersNot yet recruitingNCT06721598
- Clinical Study of Therapeutic Immunological Agent for EBV Lymphoproliferative DiseasesNot yet recruitingNCT06666153Phase 1
- Remote Multichannel Monitoring of Patients With Chronic DIseAses Using Speech technoLogies Based On Artificial intelliGenceNot yet recruitingNCT06644339Not applicable
- Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)RecruitingNCT06630104Not applicable
- A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL StudyRecruitingNCT06271252Phase 1
- Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)RecruitingNCT06052618Phase 2
- Clonal Hematopoiesis of Immunological SignificanceNot yet recruitingNCT05969821
- Virtual Rehabilitation for Cancer SurvivorsRecruitingNCT05898789Not applicable
- Liquid Biopsy to Enable Diagnostics and Monitoring for Immune-mediated Lymphoproliferative DisordersRecruitingNCT05803616
- DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.RecruitingNCT05770544Phase 2/3
- DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) DispositionRecruitingNCT05770102Phase 2/3
- DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive CancersRecruitingNCT05770037Phase 2/3
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingNCT05722886Phase 2/3
- Familial B-cell Lymphoproliferative DisordersNot yet recruitingNCT05718986
- EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ DiseasesNot yet recruitingNCT05688241Phase 1/2
- Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO StudyEnrolling by invitationNCT04996706
- Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney AllograftRecruitingNCT04989491Phase 4
- Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin LymphomasRecruitingNCT04883437Phase 2
- Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative NeoplasmsRecruitingNCT04858256Phase 2
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of ImmunityRecruitingNCT04339777Phase 2
- The OPAL Study: AVM0703 for Treatment of Lymphoid MalignanciesRecruitingNCT04329728Phase 1/2
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruitingNCT04104776Phase 1/2
- A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyRecruitingNCT03394365Phase 3
- CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)RecruitingNCT03328078Phase 1/2
- Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomasRecruitingNCT03258567Phase 2
- T Cell Therapy of Opportunistic Cytomegalovirus InfectionRecruitingNCT02982902Early Phase 1
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary ImmunodeficienciesRecruitingNCT02579967Phase 2
- Project: Every Child for Younger Patients With CancerRecruitingNCT02402244
- Pathogenesis of Hematologic MalignanciesEnrolling by invitationNCT01728402
- Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALERecruitingNCT01555892Phase 1
- Registry of Older Patients With CancerRecruitingNCT01137825
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT01137643
- Establishing a Tumor Bank in Families With Multiple Lymphoproliferative MalignanciesRecruitingNCT00131014
- Genetic Studies of Chronic Active Epstein-Barr DiseaseRecruitingNCT00032513
- A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.CompletedNCT05228470Phase 2Results posted
- Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative DisordersCompletedNCT04463615Phase 2Results posted
- Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative DisorderTerminatedNCT04337827Phase 2Results posted
- A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)CompletedNCT03744676Phase 2Results posted
- Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or DysregulationActive, not recruitingNCT03663933Phase 2Results posted
- Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell TransplantationCompletedNCT03513328Phase 1/2Results posted
- Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid MalignanciesCompletedNCT03397706Phase 1/2Results posted
- DPX-Survivac and Checkpoint Inhibitor in DLBCLCompletedNCT03349450Phase 2Results posted
- Cellular Immunotherapy for Viral Induced Cancer - EBV Positive LymphomasTerminatedNCT02763254Phase 2Results posted
- Administration of T Lymphocytes for Prevention of Relapse of LymphomasActive, not recruitingNCT02663297Phase 1Results posted
- Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood CellsTerminatedNCT02512679Phase 2Results posted
- Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT02393859Phase 3Results posted
- Chemotherapy for Relapsed Epstein Barr Virus Associated LymphomaTerminatedNCT01964755Phase 2Results posted
- Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01839916Phase 2Results posted
- Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasTerminatedNCT01805037Phase 1/2Results posted
- Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01789255Phase 2Results posted
- Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 2Results posted
- High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell LymphomaTerminatedNCT01434472Phase 2Results posted
- Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesCompletedNCT01427881Phase 2Results posted
- Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01261247Phase 2Results posted
- Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell TransplantTerminatedNCT01118013Phase 2Results posted
- Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell TransplantationTerminatedNCT01116232Phase 2Results posted
- Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT01075321Phase 1/2Results posted
- Bortezomib Plus Rituximab for EBV+ PTLDCompletedNCT01058239Phase 2Results posted
- Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin LymphomaCompletedNCT00918333Phase 1/2Results posted
- Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative DisordersTerminatedNCT00869323Phase 2Results posted
- Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell LymphomaCompletedNCT00867529Phase 2Results posted
- Methadone, Morphine, or Oxycodone in Treating Pain in Patients With CancerTerminatedNCT00726830Not applicableResults posted
- American Ginseng in Treating Patients With Fatigue Caused by CancerCompletedNCT00719563Phase 3Results posted
- Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer PainCompletedNCT00666211Phase 3Results posted
- Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With CancerCompletedNCT00661999Phase 3Results posted
- Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)TerminatedNCT00579111Phase 1/2Results posted
- Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With CancerCompletedNCT00516503Phase 3Results posted
- Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous TreatmentCompletedNCT00436618Phase 2Results posted
- Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by ChemotherapyCompletedNCT00416624Phase 2Results posted
- T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell GraftsCompletedNCT00368355Phase 2Results posted
- Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte LeukemiaCompletedNCT00345345Phase 2Results posted
- Vaccine Therapy For Patients Being Considered For Organ Transplant Who Are at Risk For PTLDTerminatedNCT00278200Phase 1Results posted
- Stem Cell Transplant for Immunologic or Histiocytic DisordersCompletedNCT00176865Phase 2Results posted
- T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic DisordersTerminatedNCT00176826Phase 2/3Results posted
- Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
- Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerCompletedNCT00089011Phase 2Results posted
- Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ TransplantationCompletedNCT00066469Phase 2Results posted
- Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancerCompletedNCT00049504Phase 2Results posted
- Bortezomib in Treating Patients With Lymphoproliferative DisordersCompletedNCT00023764Phase 2Results posted
- Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or MalignanciesCompletedNCT00002663Phase 1/2Results posted
- Treatment and Natural History Study of Lymphomatoid GranulomatosisCompletedNCT00001379Phase 2Results posted
- Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG - Second TrialActive, not recruitingNCT07264686Phase 2
- Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid BiopsyCompletedNCT06782854
- PTLD: Multicentric Retrospective StudyActive, not recruitingNCT06422715
- A Single-patient Clinical Trial of MAS825 in a Patient With XIAP DeficiencyCompletedNCT06309823Phase 3
- Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx IGH AssayCompletedNCT06112301
- Trial of Written Exposure for Metastatic Cancer Patients (EASE)CompletedNCT06042400Not applicable
- HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD ProphylaxisActive, not recruitingNCT06001385Phase 2